Rosalind Advisors
Rosalind Advisors reported 29 stocks worth $266M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are DCTH (15.6%), FENC (12.9%) and XERS (8.7%). Compared with Q1 2026, the fund opened new positions in ABVX, SPRB and PEPG, added to FENC, VSTM and TLPH, trimmed XERS, SVRA and EYPT and sold out of CGON, VRDN and DFTX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  DCTH Delcath Sys Inc | $41.6M | 15.6% | 3.3M | No change | 8 of 8 | |
| 2 |  FENC Fennec Pharmaceuticals Inc | $34.3M | 12.9% | 3.2M | +280K (+10%) | 7 of 8 | |
| 3 |  XERS Xeris Biopharma Holdings Inc | $23M | 8.7% | 2.9M | −323K (−10%) | 8 of 8 | |
| 4 |  SVRA Savara Inc | $19.6M | 7.3% | 3.2M | −26K (−1%) | 7 of 8 | |
| 5 |  VSTM Verastem Inc | $15.2M | 5.7% | 4M | +1.8M (+86%) | 7 of 8 | |
| 6 |  XFOR X4 Pharmaceuticals Inc | $15M | 5.6% | 3.2M | No change | 4 of 8 | |
| 7 |  EYPT Eyepoint Pharmaceuticals Inc | $14.1M | 5.3% | 988K | −49K (−5%) | 4 of 8 | |
| 8 | CYBIN INC | $12.9M | 4.9% | 2M | +425K (+28%) | 7 of 8 | |
| 9 |  VOR Vor Biopharma Inc Com New | $11.9M | 4.5% | 649K | −51K (−7%) | 2 of 8 | |
| 10 |  PCVX Vaxcyte Inc | $11.6M | 4.4% | 200K | −90K (−31%) | 2 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 CGON CG Oncology Inc | $6.8M | 100K |
 VRDN Viridian Therapeutics Inc | $4.9M | 250K |
 DFTX Definium Therapeutics Inc | $2.4M | 125K |
 LPCN Lipocine Inc New | $1.8M | 222K |
 AVTX Avalo Therapeutics Inc | $1.1M | 75K |
🔒 Free account: see all 6.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 SLS Sellas Life Sciences Group I | Put | $2.3M | 569K | +568,700 |
CGON CG Oncology Inc | Call | $375K | 31K | +31,000 |
EYPT Eyepoint Inc | Call | $131K | 50K | +50,300 |
 OEF Iwm 270115P00240000 | Put | $110K | 500K | +500,000 |
 XNTK Spdr Series Trust | Put | $35K | 141K | +140,600 |
🔒 Free account: see all 6.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Rosalind Advisors 13F FAQ
What does Rosalind Advisors own?
Rosalind Advisors reported 29 stocks worth $266M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are DCTH (15.6%), FENC (12.9%) and XERS (8.7%). The table above lists every position in the filing (the top 10 without an account).
What did Rosalind Advisors buy and sell in Q2 2026?
Compared with Q1 2026: 3 new positions, 7 added to, 11 trimmed and 6 sold out. New positions include ABVX, SPRB and PEPG. It sold all of CGON, VRDN and DFTX.
When will Rosalind Advisors file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Rosalind Advisors's portfolio worth?
The Q2 2026 filing reports $266M in US stocks ($269M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.